1345009-45-1

1345009-45-1 structure

Name: Vantictumab
Chemical Name: Vantictumab
CAS Number: 1345009-45-1
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Stem Cell/Wnt Wnt
Create Date: 2023-02-22 12:01:04
Modify Date: 2024-04-06 14:16:52
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2].

Name	Vantictumab

Description	Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Stem Cell/Wnt >> Wnt
Target	FZD1/2/5/7/8[1][2].
References	[1]. Davis SL, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020 Jun;38(3):821-830. [2]. Diamond JR, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020 Nov;184(1):53-62.

No Any Chemical & Physical Properties